Arie Belldegrun
CIK 1296549 · Chairman, President and CEO · last filed 2026-06-24
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$23.41M
Companies
9
Total Filings
75
Lifetime Open-Market Net
$14.95M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| URGN | Director | 408,693 | $40.88 | $16.71M | $0 | 13 | 2026-06-24 |
| ALLO | Director | 4,034,979 | $1.66 | $6.70M | $17.96M | 18 | 2026-02-04 |
| Kronos Bio, Inc. (KRON) Delisted | Director | 0 | $0.88 | $0 | $0 | 6 | 2025-06-20 |
| Ginkgo Bioworks Holdings, Inc. (DNA.WS) Delisted | Director | 694,925 | $0.01 | $4.4K | $0 | 3 | 2024-06-14 |
| Kite Pharma, Inc. (KITE) Delisted | Chairman, President and CEO | 609,160 | — | — | -$3.75M | 7 | 2017-09-27 |
| CAPRICOR THERAPEUTICS, INC. (NLTXW) Delisted | Director | 292,000 | — | — | $0 | 2 | 2011-05-12 |
| CAPRICOR THERAPEUTICS, INC. (NLTX) Delisted | Director | 324 | $13.96 | $4.5K | $0 | 1 | 2009-09-28 |
| Cougar Biotechnology, Inc. (CGRB) Delisted | Director | 0 | — | — | $727.5K | 5 | 2009-07-07 |
| Talon Therapeutics, Inc. (HNAB) Delisted | Director | 0 | — | — | $0 | 2 | 2009-02-26 |
Recent Filings · Page 5 of 8
75 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-10-05 | — | Mixed | −3,306,429 | -$575.51M | |
| 2017-09-27 | Kite Pharma, Inc. (KITE) Delisted | Mixed | +23,653 | -$4.73M | EDGAR |
| 2017-05-09 | Kite Pharma, Inc. (KITE) Delisted | Buy (P) | +17,000 | $1.17M | EDGAR |
| 2016-12-29 | Kite Pharma, Inc. (KITE) Delisted | Mixed | −22,200 | $0 | EDGAR |
| 2016-12-22 | Kite Pharma, Inc. (KITE) Delisted | Sell (S) | −3,493 | -$177.7K | EDGAR |
| 2016-08-17 | — | Buy (P) | +714,285 | $0 | |
| 2016-04-11 | — | Grant (A) | — | $0 | |
| 2016-01-14 | — | Buy (P) | +2,162,347 | $756.8K | |
| 2015-12-21 | Kite Pharma, Inc. (KITE) Delisted | Grant (A) | +28,200 | $0 | EDGAR |
| 2014-12-30 | Kite Pharma, Inc. (KITE) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.